Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28432135 | 0.89 | GAA (0.65) | GAAALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL22326350 | 0.87 | GAA (0.88) | GAAALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL12451348 | 0.87 | GAA (0.62) | GAAALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL20547085 | 0.85 | GAA (0.61) | GAAALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL9035129 | 0.85 | TDP1 (0.67) | GAAALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL17650674 | 0.85 | GAA (0.64) | GAAALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL6570943 | 0.83 | GAA (0.74) | GAAALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL24507059 | 0.82 | GAA (0.71) | GAAALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL12028883 | 0.82 | GAA (1.00) | GAAALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL3077457 | 0.82 | GAA (1.00) | GAAALDH1A1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003214-B | Substituted pyrazolo [1,5-a ] pyrimidine compounds as TRK kinase inhibitors | 阵列生物制药公司 | 2021-12-21 | — | — | CN | disclosed |
| US-10758542-B2 | Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10251889-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | Array BioPharm Inc. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180263984-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-09-20 | — | — | US | disclosed |
| EP-3299372-A1 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OFSUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-2451812-B1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-9796724-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9782415-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9682979-B2 | Substituted pyrazolo [1,5-A] pyrimidine compounds as TRK kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170119770-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20150031667-A1 | Substituted Pyrazolo [1,5-A] Pyrimidine Compounds as TRK Kinase Inhibitors | ARRAY BIOPHARMA, INC. | 2015-01-29 | — | — | US | disclosed |
| US-8791123-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20120238488-A1 | COMPOUNDS AND METHODS FOR TREATING NEOPLASIA | PHARMACELLION LTD. (GB) | 2012-09-20 | — | — | US | disclosed |
| US-20120238488-A1 | COMPOUNDS AND METHODS FOR TREATING NEOPLASIA | PHARMACELLION LTD. (GB) | 2012-09-20 | — | — | US | disclosed |
| US-20120238488-A1 | COMPOUNDS AND METHODS FOR TREATING NEOPLASIA | PHARMACELLION LTD. (GB) | 2012-09-20 | — | — | US | disclosed |
| EP-2451812-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-05-03 | — | — | US | disclosed |
| WO-2011029639-A2 | COMPOUNDS AND METHODS FOR TREATING NEOPLASIA | MEDEXIS S.A. (GR) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011029639-A2 | COMPOUNDS AND METHODS FOR TREATING NEOPLASIA | MEDEXIS S.A. (GR) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011006074-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170119770-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | TXK, FRK, LTK | GAA 4606/4885ALDH1A1 3980/4885KMT2A 3132/4885 |
| US-10251889-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | TXK, FRK, LTK | GAA 4606/4885ALDH1A1 3980/4885KMT2A 3132/4885 |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | FRK, TXK, TNNI3K | GAA 4527/4885ALDH1A1 3849/4885KMT2A 3118/4885 |
| US-20150031667-A1 | Substituted Pyrazolo [1,5-A] Pyrimidine Compounds as TRK Kinase Inhibitors | TXK, FRK, LTK | GAA 4606/4885ALDH1A1 3980/4885KMT2A 3132/4885 |
| US-20120238488-A1 | COMPOUNDS AND METHODS FOR TREATING NEOPLASIA | VHL, KRAS, TP53 | GAA 1132/4885ALDH1A1 313/4885KMT2A 600/4885 |
| US-20180263984-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | TXK, FRK, LTK | GAA 4606/4885ALDH1A1 3980/4885KMT2A 3132/4885 |
| US-10758542-B2 | Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors | LTK, TXK, FRK | GAA 4501/4885ALDH1A1 4131/4885KMT2A 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.